PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
Differential Long-Term Benefit of 2-Year Adjuvant Tamoxifen Therapy for Luminal-Type Breast Cancer: Insights From a 20-Year Follow-Up Analysis of the STO Trials
Title: Differential long-term benefit of 2-year adjuvant tamoxifen therapy for luminal-type breast cancer: Insights from a 20-year follow-up analysis of the STO trials Publication: ESMO Annals of Oncology, Breast cancer, early stage, Volume 35, Supplement 2S346, September 2024 Authors: M. Rios Romero, O. Danielsson, T. Fornander, A. Nordenskjöld, G. Read More
Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial
Title: Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial Publication: JAMA Network Open. 2024;7(11):e2447530. Authors: Laura J. van ’t Veer, PhD; Elma Meershoek-Klein Kranenbarg, MS; Marjolijn Duijm-de Carpentier, BS; Cornelis J. H. Van de Velde, MD; Miranda Read More
Incorporating Immunotherapy in the Management of Early-Stage Estrogen Receptor-Positive Breast Cancer
Title: Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancer Publication: ESMO Open - Volume 9 - Issue 11 - 2024 1 Authors: G. Nader-Marta, A. G. Waks, S. M. Tolaney, E. L. Mayer Abstract Immune checkpoint inhibitors (ICI) have been incorporated into standard treatment regimens for Read More
Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers
Title: Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers Publication: Clin Cancer Res. 2024 Nov 19. doi: 10.1158/1078-0432.CCR-24-1553. Authors: Alejandro Rios-Hoyo, Kaitlyn Xiong, Jiawei Dai, Christina Yau, Michal Marczyk, Rolando Garcia-Milian, Denise M Wolf, Laura A Huppert, Rita Nanda, Gillian L Hirst, Erin F Read More
70‑Gene signature‑guided adjuvant systemic treatment adjustments in early‑stage ER+ breast cancer patients: 7‑year follow‑up study
Title: 70‑Gene signature‑guided adjuvant systemic treatment adjustments in early‑stage ER+ breast cancer patients: 7‑year follow‑up of a prospective multicenter cohort study Publication: Breast Cancer Research and Treatment 2024 Authors: Eline E. F. Verreck, Anne Kuijer, Julia E. C. van Steenhoven, José H. Volders, Annette W. G. van der Velden, Read More
Identification of Racial Disparities (ESMO 2024)
Title: Identification of racial disparities across MammaPrint® and BluePrint® subtypes in HR+HER2- breast cancer Publication: ASCO 2024, Abstract #534 Authors: Sonya Reid, M.D., Jennifer G. Whisenant, Ph.D.; Jennifer Wei, M.D., Ph.D., Harshini Ramaswamy, M.Sc., Nicole Stivers, Ph.D., Andrea Menicucci, Ph.D., William Audeh, M.D., Tuya Pal, M.D. Background: Black women in Read More
Case Report: pCR to NAC + Pembro in High Risk Basal-type BC
Cureus, part of Springer Nature Author: Jiang et al.
Read More
